

Effect of Acoltremon Ophthalmic Solution 0.003% on Signs and Symptoms of Ocular Surface Disease in Stage I Neurotrophic Keratopathy Patients With Tear Deficiency

NCT07502378

Status	RECRUITING
Phase	Phase 4
Sponsor	University of South Florida
Enrollment	50 participants

Key Eligibility Criteria

Inclusion (4)

- Neurotrophic Keratopathy stage 1 diagnosis based on the following: Presence of 3+ fluorescein staining in central cornea and decreased corneal sensation (Cochet-Bonnet less than 4cm in the central cornea)
- Baseline unanesthetized Schirmer's test d 10 mm
- Females of childbearing potential must have a negative pregnancy test.
- Best corrected distance visual acuity (BCDVA), using corrective lenses, if necessary, in the study eye of at least +1.0 Log MAR (Snellen \leq 20/200).

Exclusion (11)

- Evidence of any active ocular infection or any intraocular inflammation.
- Evidence of any persistent epithelial defect/ulcer or any corneal scar/corneal edema.
- Presence of any other ocular conditions that require topical medications during the treatment phase.
- History of severe systemic allergies or severe ocular allergies.
- Inability to suspend topical medications 8 days prior to the starting date and artificial tears 2 hours prior to the first study visit and remain off for the duration of the study.

... and 6 more (see full listing online)

Locations (1 total)

University of South Florida/Ophthalmology, Tampa, Florida, United States